Home
Random
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
IX Biopharma Ltd.
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Summary<ref>Source: Yahoo Finance.</ref> == iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in China, Australia, and Singapore. The company operates through Specialty Pharmaceutical and Nutraceutical segments. Its lead product candidate is Wafermine, a sublingual ketamine oral wafer for the treatment of acute moderate to severe pain, as well as for major depressive disorder. The company also offers Xativa, a sublingual cannabidiol wafer for the treatment of anxiety, relieving pain, reducing inflammation, and improving sleep quality; BnoX, a sublingual buprenorphine wafer for the management of acute and chronic moderate to severe pain; and Wafesil and Silcap for the treatment of male erectile dysfunction. In addition, it offers LumeniX for skin lightening and immunity; WafeRest for the promotion of sleep; and SL-NAD+ product. Further, the company promotes and markets nutritional and supplements products through pharmacies and health food shops, as well as through online; develops and commercializes of nutraceutical products; provides laboratory services; JD and Tmall e-commerce platforms in China; and markets and distributes products in Europe. iX Biopharma Ltd. was founded in 2008 and is headquartered in Singapore.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)